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Abstract: In an effort to find new repurposed antibacterial compounds, we performed the screening of
an FDA-approved compounds library against Staphylococcus aureus American Type Culture Collection
(ATCC) 25923. Compounds were evaluated for their capacity to prevent both planktonic growth
and biofilm formation as well as to disrupt pre-formed biofilms. One of the identified initial hits
was fingolimod (FTY720), an immunomodulator approved for the treatment of multiple sclerosis,
which was then selected for follow-up studies. Fingolimod displayed a potent activity against S. aureus
and S. epidermidis with a minimum inhibitory concentration (MIC) within the range of 12–15 µM at
which concentration killing of all the bacteria was confirmed. A time–kill kinetic study revealed that
fingolimod started to drastically reduce the viable bacterial count within two hours and we showed
that no resistance developed against this compound for up to 20 days. Fingolimod also displayed
a high activity against Acinetobacter baumannii (MIC 25 µM) as well as a modest activity against
Escherichia coli and Pseudomonas aeruginosa. In addition, fingolimod inhibited quorum sensing in
Chromobacterium violaceum and might therefore target this signaling pathway in certain Gram-negative
bacteria. In conclusion, we present the identification of fingolimod from a compound library and its
evaluation as a potential repurposed antibacterial compound.
Keywords: fingolimod; biofilm; antibacterial; screening; quorum sensing; Staphylococcus aureus;
Acinetobacter baumannii; Pseudomonas aeruginosa
1. Introduction
Infections involving multi-drug resistant bacteria have become extremely harder to treat, as many
of the currently used antibiotics are less effective, which has boosted the awareness of the urgent need for
new drugs and therapeutic options in recent years [1–3]. In addition, bacteria prefer biofilm formation
(multicellular communities of cells embedded in a self-produced extracellular matrix composed of
polysaccharides, nucleic acids and proteins) as their primary growth mode, which provides the residing
cells with higher chemotolerance in comparison to free-floating (planktonic) single cells, thus making
infections notoriously hard to treat [4,5]. When adopting a biofilm lifestyle, bacteria change their
genome and proteome in ways that contribute to their survival [6,7]. Many cellular mechanisms,
involving, e.g., efflux pumps, the downregulation of key metabolic activities and switch to a dormant
state, are contributory factors making the cells within the biofilm less susceptible to most antibiotics [8,9].
Biofilm-related infections represent a majority of all bacterial infections and can affect a large variety of
organs [5,10]. They are found in up to 60% of chronic wound infections and are particularly prevalent
in infections occurring in medical devices, such as orthopedic implants and catheters, as non-biological
foreign material offers a ready surface for colonization by single bacteria [11–14]. Over 50% of all
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urinary catheters will become infected within two weeks, and up to 2% of all orthopedic alloplastic
devices and 4% of heart valves and pacemakers will eventually become infected [15,16]. In those
cases, as biofilms cannot be fully destroyed by antibiotic treatments, a chronic infection settles and the
device needs to be surgically replaced, a procedure that implicates risks and morbidity [16,17]. Thus,
the prevention of biofilm formation is the method of choice to combat device-related infections.
To date, most antibacterial treatments available have been developed to treat acute infections caused
by planktonic cells and fail to affect biofilms [18]. In many studies, the activity of new antibacterial
compounds is still evaluated exclusively by determining the minimum inhibitory concentration (MIC)
of the drug on planktonic cells. Many approaches have been taken to tackle the challenge of antibacterial
resistance combined with the natural tolerance of biofilms, including searches for new structures
among previously unavailable natural sources and the computer-based design of new molecules.
Another promising strategy is to repurpose drugs that have been developed for another therapeutic
use into antimicrobials. This approach, while bringing less novelty than screening newly synthesized
structures or natural products, has the advantage of increasing the chances of finding biologically
active hits. Additionally, compounds that have already been investigated or approved for therapeutic
use in humans are more likely to be safe and to have drug-like characteristics than new compounds,
reducing the cost and time needed for the development of a drug [19,20].
In the present study, we screened a collection of FDA-approved drugs using a previously
optimized 384-well plate-based platform that allows screening the effect of the compounds on both
the viability and biomass of the biofilm [21]. The screening was performed against Staphylococcus
aureus, an important pathogen responsible for a large variety of healthcare-associated infections
such as device-related infections, wound infections and sepsis [22]. From the FDA-approved library
(containing 774 compounds), 45 compounds were identified as highly effective in preventing the
biofilm formation of S. aureus. From these, fingolimod, a sphingosine-1-phosphate receptor modulator,
was selected for further characterization studies. We explored the ability of this drug to prevent the
formation of S. aureus biofilms as well as to disrupt pre-formed biofilms. We tested fingolimod on
other Gram-positive as well as Gram-negative bacterial species and investigated its mode of action
(MoA) via time-kill kinetics, resistance development and quorum sensing (QS) inhibition studies.
The antibacterial activity of structural analogues of fingolimod (e.g., sphingosine) has been studied
in more detail before, however, to the best of our knowledge, fingolimod’s activity against S. aureus
was not earlier reported and little is known of its anti-biofilm activity. Taken together, our findings
support that fingolimod, a drug registered to treat multiple sclerosis, has an important antimicrobial
activity and might serve as an interesting parent structure for chemical optimization efforts to obtain
new antibacterial compounds.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
All bacterial strains, their providers and the analysis performed with each, are shown in Table 1.
At the start of all experiments, unless otherwise specified, every strains (except Pseudomonas aeruginosa
and Chromobacterium violaceum) were first grown on a tryptic soy agar (TSA, LAB011, Lab M Ltd.,
Heywood, UK) plate and incubated overnight at 37 ◦C under aerobic conditions. Then, the colonies
were suspended in 5 mL of tryptic soy broth (TSB, LAB004, Lab M Ltd., Heywood, UK) in a 50 mL
Falcon tube (Greiner Bio-One, Kremsmünster, Austria) and grown to exponential phase under aerobic
conditions at 37 ◦C with shaking (220 rpm), until the culture reached a concentration of approximately
1 × 108 colony forming unit (CFU) mL−1. The culture was diluted to 1 × 106 CFU mL−1 before starting
the experiment (or to 7 × 104 CFU mL−1 for the screening). The same was done with all P. aeruginosa
strains using Lennox broth (LB) agar (LBA) (LAB168, Lab M Ltd.) plates and LB (LAB169, Lab M Ltd.)
for the liquid culture. For the QS inhibition analysis, C. violaceum was grown on LBA overnight at
27 ◦C and the colonies were used to start the experiment directly.
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Table 1. Bacterial strains, providers and analysis performed with each strain.
Bacterial Strains Provider Analyses
Staphylococcus aureus ATCC 25923
Faculty of Pharmacy of the












HAMBI collection, Faculty of
Agriculture and Forestry,





NCTC 13423 National Collection of Type







Pseudomonas aeruginosa ATCC 9027









(LMPH), University of Antwerp,
Antwerp, Belgium
Chromobacterium violaceum
ATCC 31532 ATCC, Wesel, Germany
Quorum sensing inhibition
Chromobacterium violaceum NCTC
13278 (Tn5-mutant CV026) NCTC, Salisbury, United Kingdom
2.2. Compounds
A commercial compound library, the Screen-Well FDA Approved Drug Library Version 2
(ENZO Life Sciences, Helsinki, Finland) containing 774 compounds was used for the screening with
the goal of identifying repurposed antibacterial compounds. For follow-up studies, fingolimod,
with purity ≥98%, was purchased from Carbosynth (Compton, UK). Fingolimod was dissolved into
dimethyl sulfoxide (DMSO) and sonicated for 5 min using a Branson 3800 ultrasonic bath (Cleanosonic,
Richmond, VA, USA), at 40 Hz. The antibiotics used in the resistance development experiment
(doxycycline (D3447), penicillin G (13752) and oxacillin (28221)) were all bought from Sigma-Aldrich
(St. Louis, MO, USA).
2.3. Screening of the Compound Library in 384-Well Plates on S. aureus Biofilms
The compounds were diluted in DMSO or sterile H2O, according to the provider’s instructions,
and tested at a final concentration of 10 µM against S. aureus American Type Culture Collection (ATCC)
25923. Cells were diluted in TSB at a concentration of 7.00 × 104 CFU mL−1 and grown in polystyrene
384-well plates (NuncTM 242757, Thermo Fisher Scientific, Waltham, MA, USA) in a volume of 40 µL
per well. For the pre-exposure screening, the compounds were added to the wells before the bacterial
solution to test the ability of compounds to prevent bacterial growth and plates were incubated for 18 h
under aerobic conditions at 37 ◦C with shaking (220 rpm). For the post-exposure screening, bacteria
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were grown with no compounds in the same conditions for 18 h, after which the media was changed,
and compounds were added on the pre-formed biofilms. The biofilms were then incubated for an
additional 24 h. After the incubation of the bacteria with the compounds, the antibacterial activity
of the compounds was assessed with a resazurin staining assay, followed by a crystal violet staining
assay in the same plate as described in the following sections.
2.4. Resazurin Staining
For the compound library screening, resazurin staining was performed in 384-well plates
according to the protocol previously optimized in our group [21] with following modifications.
Briefly, the planktonic solution was first transferred into a new 384-well plate and the optical density
(OD) of the planktonic solution was measured using a Varioskan LUX Multimode microplate reader
(Thermo Scientific, Vantaa, Finland). Then, 2 µL of a 400 µM resazurin (R7017, Sigma-Aldrich) solution
in phosphate-buffered saline (PBS, BR0014, Thermo Fisher Scientific) was added to the wells (for a
final resazurin concentration of 20 µM). The plate was incubated in darkness for 3–5 min at room
temperature with shaking (220 rpm) and fluorescence was measured at λexcitation = 560 nm and λemission
= 590 nm using top optics of the Varioskan LUX Multimode microplate reader. The biofilms, still in
the original screening plates, were washed once with PBS to remove the remaining planktonic cells.
Then, 40 µL of a resazurin solution at 20 µM (pre-exposure) or 40 µM (post-exposure) was added to the
wells and the plates were incubated in darkness at room temperature (RT) for 40 min with shaking
(220 rpm). Fluorescence was measured as previously described for the planktonic solution.
After the screening, subsequent resazurin staining experiments (dose–response and activity on
additional strains) were performed in 96-well plates. The working volume in each well was of 200 µL
(instead of 40 µL for 384-well plates) and the final resazurin solution concentration was 20 µM for
all bacterial strains. For Gram-positive strains, an incubation of 30 min at RT was sufficient for the
biofilms. For Gram-negative strains, the biofilms were incubated at 37 ◦C for a longer time ranging
from 1 to 1.5 h. For all resazurin (and subsequent crystal violet) assays, untreated bacteria (negative
control) and bacteria exposed to the solvent alone (DMSO 1–2.5%) were used as controls.
2.5. Crystal Violet Staining
The biofilms (previously stained with resazurin) were subjected to crystal violet staining as follows.
The resazurin solution was removed and replaced by ethanol at 100% for 15 min at RT. The ethanol
was removed, and biofilms were left to air-dry completely at RT. Then, crystal violet, diluted by 1:100
in deionized water from the 2.3% commercial solution (HT90132, Sigma-Aldrich), was added in the
wells (35 µL in 384-well plates and 190 µL in 96-well plates). After 5 min, the biofilms were washed
twice in deionized water and left to air-dry for about 10 min. The dye was solubilized in ethanol 100%
for 1 h and absorbance was measured at 595 nm using a Multiskan Sky microplate spectrophotometer
(Thermo Scientific, Vantaa, Finland). Crystal violet staining experiments subsequent to the screening
(dose–response and activity on different strains) were performed in 96-well plates at a working volume
of 200 µL per well.
2.6. Minimum Bactericidal Concentration (MBC) and Biofilm Preventing Concentration (BPC)
Minimum bactericidal concentration (MBC) is described here as the lowest concentration killing
>99% of planktonic bacterial cells (one or no colony after overnight incubation on agar) and biofilm
preventing concentration (BPC) as the lowest concentration to prevent the adherence and survival
of >99% of bacterial cells on the surface of the wells. S. aureus was grown in a 96-well plate and
exposed to fingolimod (same concentrations as for the dose–response for each strain) in pre-exposure as
described in the culture conditions section. After 18 h, in wells where no visible growth was observed
(from the MIC and higher), a volume of 50 µL of planktonic solution was transferred directly on a TSA
plate (MBC determination). The wells were then emptied of the remaining planktonic solution and
washed once with PBS. The bottom of the wells was scraped in 50 µL of PBS using a pipette tip and the
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full volume was transferred onto a TSA plate (BPC determination). All TSA plates were incubated
overnight at 37 ◦C and the presence of colonies was assessed on the next day. Untreated bacteria
(negative control) and bacteria exposed to the solvent alone (DMSO 1%) were used as controls.
2.7. Quantification of the Viable Cells in Biofilms
To quantify the activity of fingolimod on pre-formed biofilms (post-exposure) in terms of viable
cells remaining after treatment, biofilms were grown in 96-well plates in 200 µL of TSB for 18 h at
37 ◦C with shaking and then exposed to the compound for 24 h in the same incubation conditions.
The planktonic solution was removed from the wells and biofilms were washed once with PBS before
being scraped in 100 µL of PBS with a pipette tip. Then, the bacteria were serially diluted in PBS and
plated on TSA in 10 µL drops. The washing of the biofilms with PBS and serial dilutions reduced
compound carryover onto the TSA plates. CFUs were counted after an incubation at 37 ◦C overnight.
Untreated bacteria (negative control) and bacteria exposed to the solvent alone (DMSO 1%) were used
as controls.
2.8. Time-Kill Kinetic Assay
The bacterial culture was made as explained above, however, the cells were grown overnight
instead of a few hours. On the next day, it was diluted to a concentration of 1 × 106 CFU mL−1.
In 15 mL Falcon tubes (62.554.502, Sarstedt, Nümbrecht, Germany), 40 µL of fingolimod at different
concentrations (0.5 ×MIC, MIC (12 µM), 2 ×MIC, 4 ×MIC, 16 ×MIC) were added to 4 mL of bacterial
culture. For the growth control, bacteria were exposed to the solvent alone (DMSO 2%). The tubes
were then incubated at 37 ◦C with shaking (220 rpm) and a sample of 200 µL was collected from each
tube into a 1.5 mL tube (72.690.550, Sarstedt) at various time points (15 min, 30 min, 1, 2, 3, 4, 6, 8,
12, and 24 h). The samples were centrifuged at 10,000× g for 5 min at 4 ◦C and the supernatant was
discarded to limit compound carry-over. Bacteria pellets were resuspended in 200 µL of PBS and
transferred into a 96-well plate for an OD measurement (595 nm) using the Varioskan LUX Multimode
microplate reader. Bacteria were then serially diluted in PBS and 10 µL drops were seeded on TSA
plates. After an overnight incubation at 37 ◦C, colonies were counted.
2.9. Assessing Resistance Development
The bacterial culture was made like described above but it was grown overnight instead of a few
hours. On the next day, it was diluted to a concentration of 1 × 106 CFU mL−1. In a 96-well plate, 200 µL
per well of the bacterial culture were added in wells containing the compounds (fingolimod and three
antibiotic controls; doxycycline, penicillin, oxacillin) at either the MIC or half of the MIC. The plate
was incubated at 37 ◦C with shaking (220 rpm) for 24 h, after which the bacterial growth was visually
assessed. If bacterial growth was visible in the highest concentration of compound, that would indicate
an increase in the MIC (resistance development) and 10 µL of that bacterial culture was transferred into
two new wells containing 190 µL of TSB with either the same concentration or the double concentration
of compound. If bacteria only grew in the well containing 0.5 ×MIC, the compound concentrations in
the new wells were kept the same. The plate was then incubated again for 24 h and the process was
repeated for 20 days.
2.10. Quorum Sensing Inhibition Assays
The ability of fingolimod to block the QS system in Gram-negative bacteria was assessed essentially
as described previously [23,24]. Shortly, two QS reporter strains, C. violaceum ATCC 31532 and the
violacein-negative, mini-Tn5 mutant of C. violaceum CV026 were grown on LBA (for CV026 the agar
was supplemented with kanamycin at 100 µg mL−1) overnight at 27 ◦C. Colonies from LBA were
suspended in PDYT (0.5% peptone, 0.3% d-glucose, 0.25% yeast extract, 0.05% l-tryptophan, w/v)
to achieve OD600 = 0.02. In the case of CV026, the cell culture was supplemented with C6-HSL
(N-hexanoyl-l-homoserine lactone) (10007896, Cayman Chemical, MI, USA) at 0.5 µM to induce the QS
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system and subsequent synthesis of violacein, the indicator of QS induction. Then, 200 µL of bacteria
culture was added per well in two identical 96-well plates containing the compounds (2 µL per well for
a final DMSO concentration of 1% as the cell control showed unaffected violacein production). In each
96-well plate, the untreated cells were used as negative controls and quercetin (Q4951, Sigma-Aldrich)
and azithromycin (PZ0007, Sigma-Aldrich) were included as positive controls for QS inhibition and
cell viability (bactericidal activity), respectively. The plates were incubated at 27 ◦C under aerobic
conditions (200 rpm) for 22 h.
The synthesized and non-soluble violacein was collected from the first 96-well plate by
centrifugation (4000 rpm, for 20 min, 20 ◦C) and the supernatants were removed. The violacein
was dissolved in 96% (v/v) ethanol and separated from cells by centrifugation as described above.
Aliquots of 100 µL containing the violacein were transferred to a new 96-well plate and changes in
violacein production were monitored atλ= 595 nm using a Multiskan Sky Microplate spectrophotometer.
Bactericidal effects were detected using the second replica plate by adding 10 µL of 400 µM resazurin in
each well and incubating the plate for 30 min in the darkness at 27 ◦C (220 rpm). After centrifugation,
100 µL of each well was transferred into a new 96-well plate and the changes in viability (i.e., reduction
of resazurin into resorufin) was recorded as described above using the Varioskan LUX multimode
plate reader.
2.11. Statistical Analysis
Screening performance was monitored by the calculation of the screening window coefficient (Z’)
as described in [25]. The statistical significance of the results was assessed using a Student’s t-test and
significance was indicated as follows: * if p < 0.05, ** if p < 0.01 and *** if p < 0.001.
3. Results and Discussion
3.1. Screening FDA-Approved Compounds Identifies 45 Anti-Biofilm Agents against S. aureus
The anti-bacterial screening of the FDA library was performed in 384-well plates. The ability of
the compounds to prevent bacterial growth and biofilm formation (pre-exposure) as well as affect
pre-formed biofilms (post-exposure) was separately measured at 10 µM. The identities of the tested
compounds and their activities during the primary screenings are listed in the Supplementary Table S1.
The effect of the compounds on planktonic cells was monitored by measuring the turbidity of
the cells (OD at 595 nm) and the viability by resazurin staining. In the case of the biofilms, we also
used resazurin staining for monitoring changes in viability, while crystal violet staining was applied
to measure changes in total biomass. The effects of the tested compounds on both the planktonic
cells and biofilms in comparison to untreated bacterial controls are shown in Figure 1. A threshold of
80% inhibition was empirically set to select the active compounds. When considering the turbidity
and viability results, 59 compounds were identified as potential hits against the planktonic cells in
the pre-exposure mode of assay. A lower number of compounds (45) were identified as potential
anti-biofilm hits, which reduced both the viability and biomass production of S. aureus by at least 80%
in the pre-exposure mode of assay. These 45 compounds were also among the hits against planktonic
cells, except for one that was active in preventing biofilms but not against planktonic cells, for a total of
60 hits in the pre-exposure assay. In the post-exposure assay, no new compounds were identified with
specific effects on already pre-formed biofilms. Overall, 32 compounds were active against planktonic
cells in post-exposure, all of which were also identified as hits in the pre-exposure assay. From these,
24 were found to reduce more than 80% of the viability of the pre-formed biofilms, but none of these
compounds considerably reduced the total biomass of the pre-formed biofilms. This is not unexpected
as mature biofilms, as mentioned earlier, are known to be very tolerant to antimicrobial chemotherapy.
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Figure 1. Screening of an FDA-approved compound library against S. aureus in pre-exposure (a and c
panels) and in post-exposure (b and d panels): (a,b) inhibition of planktonic cell viability and turbidity;
and (c,d) inhibition of the biofilm biomass and viability. Results are averages from two separate
experiments with each one replicate per compound.
3.2. Hit-to-Lead Identification Process
Figure 2 summarizes the selection process carried out after the primary screening. As described in
the previous section, a total of 60 hit compounds were identified in the initial screening against either
the planktonic cells (turbidity and viability), the biofilms (viability and biomass production) or both.
First, these 60 hits were retested at 10 µM in a 384-well plate (Supplementary Table S2) with the same
combination of assays used during the primary screening to confirm the screening results. Following
this, five initial hits were readily excluded as they did not show an inhibition of the planktonic cells
nor the S. aureus biofilms over 80%. The known therapeutic indications of the remaining 55 confirmed
hits were explored. Based upon this, it was learned that 48 of these hits were listed in the information
provided by the library supplier as being either approved antibiotics or already widely known for
their antibacterial activity (41), or they had been approved for the treatment of cancer (7) and were
excluded due to their likeliness to have high cytotoxicity.
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For the seven remaining hits, a literature search was undertaken to evaluate their potential as
repurposed antibacterial agents. We identified four active hits (sertaconazole, econazole, miconazole
and sulconazole), which were approved antifungal drugs of the imidazole class. They are known to
inhibit the synthesis of ergosterol, the main sterol of fungal membranes, as well as other important
components [26,27]. Imidazoles are currently the focus of numerous medicinal chemistry efforts
and many derivatives have shown potent antibacterial and anti-biofilm activity [28–31]. Therefore,
it is not surprising that they were also identified as positive hits in our study. Of the remaining
three hits, one was auranofin, a gold-containing drug, which has been approved for the treatment
of rheumatoid arthritis. Auranofin’s potential as a repurposed antimicrobial agent against various
organisms, including S. aureus, has already been explored [32,33], and it was therefore excluded from
further analysis. The second remaining hit was acyclovir, a known antiviral commonly used for the
treatment of viruses of the herpes family, which to the best of our knowledge has not yet been reported
as an anti-bacterial compound, and is currently being studied in detail by our group.
The last identified hit compound was fingolimod, and it was selected as the lead for further
characterization. Fingolimod (Figure 2), 2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol (FTY720)
is an analogue of sphingosine 1-phosphate (S1P) that has been approved for the treatment of relapsing
multiple sclerosis. It is a synthetic derivative of a natural compound, myriocin, isolated from the
fungus Isaria sinclairii [34,35]. It acts as an antagonist to S1P receptors located on lymphocytes and
prevents those cells leaving the lymph nods, causing a modulation in the immune response through a
redistribution of the lymphocytes [36]. On the other hand, sphingosine is a common sphingoid base
naturally occurring in mammalian cells. The sphingoid base is the structural unit of sphingolipids,
which are structurally diverse molecules involved in many biological functions such as inflammation,
cell differentiation and apoptosis [37,38]. The therapeutic potential of sphingoid bases and sphingolipids
has been widely explored for the treatment of a variety of diseases, including cancer, ischemia and
immune diseases [39–41]. Interestingly, sphingosine has been found to be important in the immune
defense of healthy airways as a lack of sphingosine increased their susceptibility to bacterial infections,
while the administration of sphingosine has been shown to prevent or reduce bacterial infection [42–45].
Sphingosine has also been reported to act as an antibacterial amino alcohol in the skin [46–48]. Overall,
many recent studies have proved that sphingosine and some of its derivatives have antibacterial activity
against a variety of species including, among others, P. aeruginosa, Acinetobacter baumannii, Escherichia coli,
S. aureus and Streptococci species [42,44,46,47,49–51]. A sphingosine coating of endotracheal tubes has
even recently been tested against P. aeruginosa, A. baumannii and S. aureus and it showed a great capacity
to prevent bacteria adherence and protection from ventilator-associated pneumonia (VAP) in vivo [52].
A recent MoA study has reported that sphingosine causes the rapid permeabilization of the bacterial
membrane of P. aeruginosa and S. aureus through the binding of sphingosine’s protonated nitrogen
group with cardiolipin, a negatively charged membrane protein [53]. In particular, fingolimod’s
therapeutic potential has been investigated for many conditions, mainly for various autoimmune
diseases [54,55]. However, its antibacterial activity has not been extensively studied, although this drug
is reported to display a potent activity against planktonic cells of the gut bacteria Clostridium perfringens
and to provide in vivo protection against P. aeruginosa [43,56]. Even though conclusions from studies
made on various fingolimod structural analogues could probably be applied to fingolimod, the activity
of fingolimod itself against Gram-positive strains and biofilms has not been studied, to the best our
knowledge, and little is known of its MoA. Based upon this, we set out to investigate the extent of
fingolimod’s antibacterial activity and to gather information on its mechanism of action.
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3.3. Concentration–Response Effect of Fingolimod against S. aureus Biofilms
First, the effect of different concentrations of fingolimod on S. aureus biofilms was investigated
using the pre- and post-exposure assay modes with resazurin and crystal violet assays (Figure 3).
The MIC of fingolimod (lowest concentration at which no growth was visible and at which the OD
of the planktonic cells was the same as the media control (inhibition of 100%)) was measured to be
between 12.5 and 15 µM (depending on the replicates), at which concentration fingolimod prevents
both the growth of planktonic cells and biofilm formation. In post-exposure, although not completely
disrupting the biofilms, fingolimod at 200 µM did have a substantial effect on the pre-formed 18 h-old
biofilms, as it reduced the viability and total biomass by about 70–80% after 24 h of incubation.
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Figure 3. Inhibition of S. aureus in pre-exposure (a) and in post-exposure (b) assays caused by different
concentrations of fingoli od. Results are expressed as the average inhibition percentage of the
planktonic cells or the biofil s in co parison ith the untreated controls ± SD. Results are fro four
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We also verified if the pre-exposure activity of fingolimod was bacteriostatic or bactericidal.
S. aureus was exposed to fingolimod for 18 h in the same way as for the concentration–response
experiment. In wells where no bacterial growth was visible (exposed to a fingolimod concentration
above the MIC), the planktonic as well as possible adherent cells scraped from the bottom of the
wells were separately transferred onto TSA plates for measuring viable cells (CFU counts) after an
overnight incubation (Table 2). This allowed confirming that fingolimod does kill all S. aureus cells and
almost completely prevents the formation of adherent colonies at a concentration as low as 15 µM,
which is therefore not only the MIC, but also the minimum bactericidal concentration (MBC) and the
biofilm preventing concentration (BPC). MBC is defined here as the lowest concentration killing >99%
of planktonic bacterial cells (one or less colony after overnight incubation on agar) and BPC as the
lowest concentration to prevent the adherence and survival of >99% of bacterial cells on the surface of
the wells.
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Table 2. MBC and BPC confirmation of fingolimod against S. aureus after a pre-exposure treatment.
Results are expressed as the percentage of replicates for which >99% of cells were killed (one or less
colony counted) (n = 9, three separate assays with each three replicates).
% of Replicates with >99% Cells Killed
(Fingolimod) Planktonic Cells Adherent Cells
10 µM 0 0
12.5 µM 11 11
15 µM 100 (MBC) 100 (BPC)
25 µM 100 89 1
50 µM 100 89
1 One replicate out of nine had <99% cells killed.
3.4. Reduction in the Count of Viable Cells in Pre-Formed S. aureus Biofilms Exposed to Fingolimod
We utilized resazurin and crystal violet assays to measure the effects of fingolimod on the viability
and biomass of S. aureus biofilms. Crystal violet was performed on fixated biofilms and dyes, all
negatively charged surfaces, including the dead cells and the remaining matrix. In contrast, the
redox-based resazurin staining does discriminate live cells from dead cells via the specific reduction of
resazurin into its fluorescent product resorufin by live cells. As this assay depends on the metabolically
active cells, the dormant cells with reduced/lacking metabolic activity fail to be detected. Because
biofilms are communities composed of cells displaying various degrees of metabolic activity, including
nearly inactive/dormant cells, this means that an important part of a biofilm’s population cannot be
typically detected with resazurin. Among those cells are also persisters, which are unaffected by
most antibacterial compounds and can reactivate and restart growth after antimicrobial treatment [57].
Furthermore, it is possible that resazurin does not penetrate all biofilms with the same kinetics, resulting
in a lower “viability” being detected at a certain time point, despite the potential presence of live cells
deeper inside the biofilms. Therefore, even if resazurin staining indicates that a biofilm is entirely
inactive, the possibility that some cells are still alive cannot be precluded.
Based upon this, we decided to further quantify the activity of fingolimod on pre-formed 18 h-old
S. aureus biofilms by performing a viable cell count after a 24 h-fingolimod treatment. This would
allow us to confirm if the 70–80% inhibition previously observed (Figure 3) would correspond to a
similar level of reduction in the viable cell count. Figure 4 shows that fingolimod reduces the number
of viable cells inside a pre-formed biofilm in a concentration-dependent manner down to a statistically
significant 1-log reduction at 150–200 µM, which represents a 90% reduction in the number of cells.
This confirms that fingolimod does reduce the count of live cells within a pre-formed biofilm and it is
aligned with the previous results of the resazurin and crystal violet staining.
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Figure 4. Log10 of the CFU count of S. aureus pre-formed biofilms treated with different concentrations
of fingolimod (post-exposure) for 24 h. Untreated biofilms are used as controls. Results are from three
distinct experiments, each with two to three biofilm replicates for all concentrations ± SD. (* p ≤ 0.05,
*** p ≤ 0.001).
3.5. Time-Kill Kinetic Effect of Fingolimod against S. aureus
For a more in-depth investigation of the activity of fingolimod against S. aureus, we performed a
kinetic (time-kill) study by counting the CFU and measuring the OD of the bacterial culture over time
whe exposed to different con entrations of fingolimod (ranging from 0.5 ×MIC to 16 ×MIC) with
MIC set at 12 µM for this exp rime t (Figure 5). The changes in OD over time demonstrate that no
concentration of fingolimod from the MIC and higher allowed visible growth of th bacteria for 24 h
a d only the culture containing 0.5 ×MIC (6 µM) had an increasing OD similar to the growth control.
The other tested concentrations of fi olimod had a similar effect on the S. aureus culture, with a rapid
decrease in the number of live cells starting within 2 h of incubation. All c centrations from th
MIC and abov caus d at l ast a 3-log reduction or more, after 12 h. However, the am unt of CFU
always started i creasing between 12 nd 24 h, suggesting that, even when no CFU w re counted at
certain time points, a small fraction of cells survive the treatment and st rted to grow again after the
treatm nt started to los efficacy. The survival of those cells with all fingoli od co centrations is not
unusual as it as b en proven that within all populations of bacteria, t er are al ays persisters that
survive treatment, regardless of the concentration of antibiotic used [57]. Another explanation could be
the rapid development of resistance against fingolimod by some of the cells in the cultures, a possibility
that we investig te here, further on. This time-kill experiment demo strates the strong ability of
fingolimod to reduce the num er of bacteria in a culture in a short period of time. Our findings show
that fingolimod becomes ctive duri the early exponential growth ph se (after 2 h of incub tion),
indicating that its MoA is li ked with t e inhibition of one or more key metabolic pathways.
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3.6. Resistance Development of S. aureus against Fingolimod
With the development of antibacterial resistance, the so-called “super bugs” have emerged, which
are resistant to most, if not all, available antibiotics [3]. In this context, and considering the results
obtained in the time-kill assay, we then decided to investigate whether S. aureus develops resistance
against fingolimod by exposing the cells to a sub-inhibitory concentration of the drug in a 20 day
period. Well characterized model antibiotics (doxycycline, penicillin G and oxacillin) were used as
references and the bacteria were exposed to the MIC and 0.5 ×MIC every day. After 24 h, if bacterial
growth was visible, some bacteria were transferred into new media containing the same concentration
as well as a 2-fold concentration of the compound. This was repeated for 20 days to see if the MIC
would increase over time.
Results of the resistance development are shown in Figure 6. As earlier, the MIC of fingolimod
was set at 12 µM and it quickly increased by 2-fold by day 2. However, no further increase in the
MIC was observed for the whole duration of the experiment. In contrast, a 4-fold increase in the MIC
was observed for doxycycline, the best performing control in this study, while an increase of nearly
100-fold and 1000-fold was observed for oxacillin and penicillin G, respectively. Considering that the
MIC of fingolimod can slightly vary between 12 and 15 µM in each experiment, it is possible that the
2-fold increase in the MIC observed here was not an indication of resistance development, but simply
of the MIC being set slightly too low at the beginning of the study. The absence of any further increase
in the MIC after that early doubling support this possibility. Overall, this indicates that resistance
would only be developing slowly against fingolimod and that its mechanism or its interaction with the
target is likely to be different from those of the control antibiotics. This finding further advocates that
fingolimod could also be used as an antibacterial drug, as it does not induce resistance and could even
be used in combination with other antibiotics.
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Figure 6. MIC doubling over time for S. aureus exposed to sub-inhibitory concentrations of (a) fingolimod;
(b) doxycycline; (c) penicillin G; and (d) oxacillin for 20 days. Results are the average obtained for two
to three biological replicates.
3.7. Activity of Fingolimod on Additional Bacterial Strains
Further on, we investigated the spectrum of the antibacterial activity of fingolimod by testing it
against different pathogenic bacterial species, such as Gram-positive S. epidermidis and Gram-negative
A. baumannii, E. coli and P. aeruginosa. In the case of A. bau annii, we used two different strains
for this experiment, the reference strain National Collection of Type Culture (NCTC) 12156 and the
multi-drug resistant and strong biofilm producer NCTC 13423 [58]. Two different clinical P. aeruginosa
strains, ATCC 9027, a non-virulent antibiotic-sensitive strain [59] and PAO1, a strain widely used in
research as a model opportunistic pathogen, were tested in addition to two environmental strains,
ATCC 700829 and ATCC 15442. The activity of fingolimod on S. epidermidis was very similar to what
was observed with S. aureus, as evidenced with the resazurin and crystal violet assays (Figure 7).
The compound was also quite effective against A. baumannii, with an MIC of 25 µM for both strains,
indicating that fingolimod is not affected by the resistance mechanisms of the A. baumannii NCTC
13423 strain. The bactericidal activity of fingolimod against the multi-drug resistant A. baumannii
NCTC 13423 strain, was further confirmed using viable cell counts, in a similar way as with S. aureus
(Table 3). Fingolimod killed all planktonic cells (MBC) in 78% of the replicates between at 100 µM,
but it did not prevent the survival of all adherent cells (BPC) at any concentration up to 100 µM.
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Table 3. MBC and BPC confirmation of fingolimod against A. baumannii NCTC 13423 after a pre-exposure
treatment. Results are expressed as the percentage of replicates for which >99% of cells were killed
(one or less colony counted) (n = 9, three separate assays with each three replicates).
% of Replicates with >99% Cells Killed
(Fingolimod) Planktonic Cells Adherent Cells
12.5 µM 0 0
25 µM 44 11
50 µM 56 11
100 µM 78 11
A lower inhibitory activity was observed against E. coli (Figure 7), which was mainly targeted at
biofilm formation, while no planktonic bacteria appeared to be killed. This could be due to fingolimod
reducing biofilm formation, by QS inhibition for example, or affecting biofilm integrity, making it more
brittle and resulting in some biofilm being broken and lost during manipulations. A viable cells (CFU)
count was done for both planktonic cells and biofilms after treatment with fingolimod for 18 h to see
if the inhibition of the E. coli biofilms was also translating into a reduction in the viable cells count.
Fingolimod reduced by less than a log the amount of CFU from both the planktonic solution and the
biofilms, thus, although some biofilm-specific inhibition is suggested by the resazurin and crystal
violet assays, it does not translate into a large reduction in the amount of live cells within the biofilm
(Figure A1).
Fingolimod also showed a limited activity against certain strains of P. aeruginosa. It visibly reduced
the planktonic and biofilm growth of P. aeruginosa ATCC 9027 from 100 µM, but only inhibited the
planktonic cells of PAO1 without affecting the biofilm formation (Figure 7). Since ATCC 9027 strain
is known as antibiotic-sensitive, it is not surprising to find that this strain is the most susceptible to
fingolimod, while the pathogenic PAO1 is more tolerant to it. In addition, fingolimod displayed no
important inhibitory activity against the two environmental strains of P. aeruginosa (ATCC 700829
and ATCC 15442) (Supplementary Figure S1). Fingolimod has previously been reported to prevent
P. aeruginosa airway infection in mice and to have a strong in vitro activity against this species with an
EC50 of 1.9 µM [43]. We did not observe an activity nearly as strong, but a difference in the bacterial
strains and the experimental conditions might explain this discrepancy. Overall, these results indicate
that fingolimod has a broad spectrum of activity, with a stronger activity against Gram-positive than
Gram-negative bacteria. Fingolimod displayed here a lower activity range than what has been observed
for its analogue sphingosine and the susceptibility of the different species was also quite different than
what was reported for sphingosine [49,53].
Fingolimod was also tested against S. epidermidis, A. baumannii and E. coli using the post-exposure
assay (Figure A2). In the case of S. epidermidis, the results were aligned with those obtained for S. aureus.
However, in the case of the Gram-negative species, fingolimod did not show any activity, which is
not surprising considering the well reported increase in resistance and tolerance factors expressed
in mature bacterial communities [5,8,60]. It is possible that the penetration of fingolimod into the
biofilm could be affected. Alternatively, if the MoA of this compound is based on affecting metabolic
pathway(s), a lower metabolic activity within the biofilm could be responsible for the compound’s
lower efficacy against a pre-formed biofilm [9].
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3.8. Quorum Sensing Inhibitory Effect of Fingolimod
We then investigated the possible effect of fingolimod on QS, an important bacterial communication
system that allows the coordination of many social behaviors, like the formation of a biofilm,
when the population reaches a certain cellular density [61,62]. The molecules used for QS are called
autoinducers (AIs) and in Gram-negative bacteria, they are generally acyl-homoserine lactones (AHLs),
while Gram-positive bacteria use small peptides and both types of bacteria can use another kind of
molecule called AI-2 [61,62]. C. violaceum is a Gram-negative strain that serves as an excellent model
for the study of QS inhibitors (QSIs), since one of its QS-regulated behaviors is the production of a
violet pigment called violacein. Its AHL signal is based on CviI/CviR, an homolog of the LuxI/LuxR
synthase and receptor system that was first described in Gram-negative bacteria [63]. Rather than only
recognizing the AHL from its corresponding synthase CviI, CviR has been reported to respond to a
wider range of AHLs that have side chains from four to eight carbons in length [63,64].
Fingolimod’s chemical structure (Figure 2) resembles some of the previously reported antagonists
of the receptors in the LuxR family and one of the AHL analogs able to inhibit AHL synthesis by
binding to its synthase [64,65]. This similarity in structure with known inhibitors of QS suggests that
fingolimod could be a QSI and although we observed that fingolimod does have a bactericidal activity
against certain Gram-negative strains like A. baumannii, a biofilm-specific inhibition was observed
against E. coli. Based upon this, we decided to investigate the possibility that fingolimod might be a
QSI for some Gram-negative strains.
A platform based on the use of C. violaceum as a reporter strain was previously optimized and
has been successfully used in chemical screens by our group [23]. This platform incorporates the
measurement of both cell metabolic activity and violacein production in C. violaceum ATCC 31532,
a wild-type strain, as well as CV026, a mutant that is AHL-deficient and needs an external AHL
(C6-HSL) to be supplemented in order to produce violacein. The addition of the metabolic activity
measurement allows to confirm that the QS inhibition observed is not due to toxicity and the use
of CV026 allows the distinction between QS inhibitors (QSIs) and quenchers of the AHL signal,
called quorum-quenchers (QQ) [23,66]. While bactericidal compounds will inhibit the metabolic
activity of the cells, QSIs (including QQs) will only inhibit the violacein production.
Using this platform, we tested fingolimod at various concentrations (Figure 8), along with the
QSI control quercetin, a flavonol with a reported QSI activity, and a bactericidal control (with no
QSI activity), azithromycin [67]. Fingolimod showed no noteworthy reduction in the metabolic
activity of the wild type strain, but it did show a clear concentration-dependent inhibition of the
violacein production. This demonstrates that fingolimod acts as a QSI against C. violaceum. However,
while the violacein production of the mutant strain CV026 was completely inhibited from 25 µM
onward, the metabolic activity of that strain was also decreased in a concentration-dependent manner.
Therefore, especially with high concentrations, in addition to being a QSI, fingolimod seems to be also
bactericidal against this strain. Nevertheless, the QSI effect was much stronger than the reduction in
viability at 25 µM, which suggests that, at this concentration and below, fingolimod targets the QS
in the reporter strain. The different results obtained with both strains of C. violaceum might reflect a
different susceptibility to fingolimod that is unrelated to the AHL-deficiency of CV026.
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Figure 8. Viability and quorum sensing (QS) inhibition of C. violaceum (a) ATCC 31532 and
(b) CV026 by fingolimod, quercetin (QS inhibitor (QSI) control) and azithromycin (bactericidal control).
Concentrations are in µM and the results are expressed as percentages of inhibition in comparison with
untreated controls. Results are from two different experiments performed with two technical replicates
for each condition ± SD.
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As the QS systems between Gram-positive and Gram-negative bacteria are different, it is highly
likely that fingolimod shows no QS inhibition activity against Gram-positive bacteria. Moreover,
QS molecules can vary within the Gram-negative species, suggesting that fingolimod may not act as
a QSI against all Gram-negative bacteria [61,62]. On the other hand, the LuxI/LuxR homologs have
been reported in more than 100 Gram-negative species and more than 200 species use AHLs as QS
signals, which implies that fingolimod still has a broad QSI activity against Gram-negative bacteria [68].
Since QS control biofilm formation as well as the expression of many virulence and pathogenic factors,
QSIs have been the subject of a lot of attention in recent years as a promising alternative strategy to
fight biofilms. QSIs can keep bacteria in the more susceptible planktonic state, which can increase
the efficacy of antibiotics in a combination therapy [69]. Additionally, since they do not target an
essential function of the bacterium, they do not apply any direct selective pressure, limiting the risks of
resistance development [68,69].
4. Conclusions
To find new repurposed antibacterial compounds, we screened an FDA-approved compound
library containing 774 compounds against S. aureus. The activity on both the planktonic cells and
biofilms was assessed to select hits that would be effective enough to prevent biofilm formation.
From the total of 60 originally identified hits, we performed a selection process that led to the
identification of fingolimod. Fingolimod is an analogue of sphingosine 1-phosphate (S1P) that is
currently used in the treatment of relapsing multiple sclerosis. Its activity against bacterial biofilms has
not been explored previously, and we showed here that it inhibits the growth of both the planktonic cells
as well as the formation of S. aureus biofilms. We also provided proof of its potent bactericidal activity
against staphylococcal strains and modest to strong activity against diverse Gram-negative species,
including the multi-drug resistant A. baumannii NCTC 13423 strain. We showed that, fingolimod is
likely to target metabolically active cells in Gram-positive strains as it starts showing the observable
killing of viable cells during the early stages of growth. In Gram-negative strains, while fingolimod
displayed a bactericidal activity against some strains, we present here the first report of fingolimod
(or any sphingosine analogue) having a QS-inhibitory activity against C. violaceum. Additionally,
some multi-drug resistant strains were susceptible to fingolimod, suggesting a different MoA than
common antibiotics. Interestingly, no antibacterial resistance was developed by S. aureus against
fingolimod during a 20 day study. Fingolimod has been proven safe and stable for use in humans, as it
is already an approved drug. It can serve as a good starting structure for optimization as the existence
of fingolimod analogues with higher antibacterial activity suggests. We provide solid in vitro data in
support of exploring this family of compounds for antibacterial and anti-biofilm therapeutics.
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Figure A1. CFU count of E. coli planktonic solution and biofilm after an 18 h treatment with 
fingolimod in the pre-exposure mode. Results are from two distinct experiments with each three 
biofilm replicates for all concentrations ± SD. 
Figure A1. CFU count of E. coli planktonic solution and biofilm after an 18 h treatment with fingolimod
in the pre-exposure mode. Results are from two distinct experiments with each three biofilm replicates
for all concentrations ± SD.
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